A major Canadian clinical trial is putting artificial intelligence into a practical hospital setting, with researchers launching a randomized controlled study across 13 Ontario hospitals to determine whether technology can help predict and prevent delirium among hospitalized patients. The trial is expected to involve approximately 15,000 patients, making it one of the largest studies of its kind in the Canadian healthcare system.
The project, known as the AI Models (AIM) to Prevent Delirium trial, is focused on a condition that affects roughly one in four adults admitted to hospital with medical or surgical problems. Researchers will assess whether identifying patients at greater risk earlier can help hospital teams concentrate prevention measures on those most likely to benefit.
The initiative adds to the growing use of AI in healthcare, particularly in areas where hospitals face pressure to improve patient outcomes while managing limited staff and resources. Rather than replacing clinical decisions, the trial is designed to examine whether AI-supported risk assessment can help healthcare workers identify vulnerable patients and prioritize preventive care. The project is being funded by Ontario’s Ministry of Health in partnership with Ontario Health and brings together researchers, clinicians, patients, caregivers and healthcare organizations.
AI Trial Targets a Costly and Often Preventable Hospital Complication
Delirium is characterized by a sudden change in mental state that can leave patients confused, disoriented, distressed or agitated. It can be particularly difficult for families to manage because symptoms can develop quickly during an already stressful hospital stay.
The condition is also associated with serious consequences. Delirium can contribute to longer hospital stays, higher healthcare costs, dementia and increased mortality. Researchers estimate that approximately 500,000 Canadians experience delirium each year, while the additional cost associated with an episode can reach about $11,000 per hospital admission.
The scale of the problem makes prevention an important issue for hospitals dealing with an aging population and increasing demand for care. Yet prevention is not always straightforward. Patients may require regular attention to factors such as nutrition, sleep, hydration, mobility, medication and their underlying medical condition.
Research indicates that as many as 40% of delirium cases may be preventable. The challenge for hospitals is maintaining those preventive measures consistently across large numbers of patients while healthcare professionals manage competing clinical priorities.
The AIM trial is intended to address that operational challenge. The system will assess patient information to identify individuals considered to have a higher risk of developing delirium. Hospital staff can then use that information to determine where additional preventive attention may be most useful.
For hospitals, the potential value goes beyond identifying a medical risk. If the approach proves effective, it could help direct limited clinical resources toward patients who require closer monitoring. That could make prevention programs easier to implement at scale without requiring hospitals to provide the same level of intensive monitoring to every patient.
Dr. Amol Verma, the project’s principal investigator, said the partnership is intended to examine whether AI can be used safely and effectively while bringing together technology researchers, healthcare teams, patients, caregivers, hospital leadership and policymakers.
The involvement of patients and caregivers is particularly relevant because delirium can have a significant emotional impact on families. Nicole Lafreniere-Davis, a patient partner involved with the trial, described the fear and confusion experienced by her family during her husband’s delirium episode.
Ontario Partnership Tests Whether AI Can Improve Delirium Prevention
The trial is being conducted through a broad partnership that includes the GEMINI research network at Unity Health Toronto, the University of Toronto, the Centre for Quality Improvement and Patient Safety, the Regional Geriatric Program of Toronto, the Centre for Advancing Collaborative Healthcare & Education and the Toronto Academic Health Sciences Network, alongside the participating hospitals.
Its randomized controlled design is important because it allows researchers to evaluate whether the AI-supported approach actually improves outcomes compared with existing hospital practices. A successful prediction model alone would not necessarily demonstrate that patients benefit. The study must determine whether acting on those predictions leads to better prevention and care.
That distinction is becoming increasingly important as healthcare organizations consider adopting AI-based technologies. Hospitals are under pressure to improve efficiency, but clinical technology must demonstrate measurable value without creating additional burdens for already stretched healthcare teams.
The AIM trial therefore provides an opportunity to examine both the clinical and operational sides of AI adoption. Researchers can assess whether the technology identifies high-risk patients effectively while also examining whether staff can incorporate those assessments into everyday hospital workflows.
The potential implications are significant. If the trial demonstrates that earlier identification of high-risk patients can increase the effectiveness of delirium prevention, the approach could offer hospitals a more targeted way to organize preventive care. It could also provide evidence for healthcare policymakers considering wider use of AI-supported clinical tools.
Dr. Barbara Liu, Executive Director of the Regional Geriatric Program of Toronto and a co-investigator, has highlighted a long-standing problem in delirium care. Hospitals have known for years that many cases can be prevented, but sustaining prevention programs has been difficult because of the resources available to healthcare teams.
This is where the trial’s focus on prioritization becomes particularly relevant. Instead of expecting staff to continuously monitor every patient at the same intensity, the technology could help highlight those who require greater attention.
However, the study will ultimately need to demonstrate that this approach works in real hospital environments. Accuracy, clinical usefulness, staff adoption and patient outcomes will all matter in determining whether the technology can move beyond research into broader practice.
The launch across 13 hospitals gives researchers an unusually broad setting in which to test those questions. With approximately 15,000 patients expected to participate, the trial could generate substantial evidence on how AI can be incorporated into routine hospital care.
For Canada’s healthcare system, the outcome could have implications beyond delirium. A successful model for combining clinical expertise with technology could influence how hospitals approach other preventable complications and resource-intensive conditions. For now, the AIM trial represents a significant test of whether AI can move from promise to measurable value at the bedside, while keeping patient safety and clinical judgment at the center of its use.
